Portfolio News

ET Startup Awards 2018: Top Innovator award goes to SigTuple

The Economic Times

July 25, 2018

SigTuple’s core product is an AI-based platform that processes visual medical data from different devices and can train, validate and execute artificial intelligence and machine learning powered models to detect diseases or flag abnormalities that need further medical investigation. This eliminates the need for medical experts to be physically present for examinations.

Currently, SigTuple uses the platform, called Manthana, to provide solutions for automated analysis of peripheral blood smears. It has also built a smart device that enables digitisation of different biological samples like blood, urine and semen. This device, called AI100, is powered by a graphics processing unit that enables the smooth running of its artificial intelligence models without the need for cloud connectivity.

In effect, SigTuple’s solutions help labs and hospitals scale by implementing a hub-and-spoke model.

“The award is a big recognition for us, especially coming from such an eminent jury and The Economic Times. It is a big motivation for what we are trying to achieve. We are trying to make a difference to healthcare,” said Rohit Kumar Pandey, CEO of SigTuple.

The company recently raised $19 million in a Series B fundraising round led by Accel Partners and IDG Ventures, with participation from Endiya Partners, pi Ventures, Flipkart Group CEO Binny Bansal, VH Capital, and Axilor Ventures. Flipkart cofounder Sachin Bansal was an early investor in the company. SigTuple has been working on commercialising its products since January.

“We want to bring out our solutions for urine and semen analysis by the end of the year. Our retinal scan solution, we want to get to beta mode by the end of the year. We have also applied for US FDA approvals. The plan is also to evaluate our solutions in emerging markets like Bangladesh and Indonesia,” said Pandey. The problem that SigTuple is solving is unique, said Flipkart cofounder and jury member Sachin Bansal. “They ‘look’ for diseases in blood and urine. They can soon move to X-rays and other categories. The space they are operating in is huge. The team is very strong technically. I was one of the first investors in the company. I have seen the product myself. It is very promising.”